Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021

<br /> Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021<br />

Discussion to feature diversified clinical pipeline with five active programs

PR Newswire


CRANFORD, N.J.

,

Sept. 14, 2021

/PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga’s All Access Show for a 20-minute interview on

Friday, September 17, 2021

at

10:10 am ET

.

Investors may tune in to the interview with Citius Chairman

Leonard Mazur

by visiting

Benzinga’s livestream channel

.

During the interview, Mr. Mazur will discuss advancements in the Company’s late-stage clinical pipeline, including the recent addition of I/ONTAK (E7777), a novel oncology asset with an attractive near-term revenue opportunity and substantially de-risked path to support commercial success.


About Citius Pharmaceuticals, Inc.


Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok

®

, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial.  Mino-Lok

®

was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19.  For more information, please visit

www.citiuspharma.com

.


Investor Relations for Citius Pharmaceuticals:



Ilanit Allen


Vice President, Corporate Communications and Investor Relations

T: 908-967-6677 x113

E:

[email protected]

Citius_Logo

Cision
View original content:

https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-join-benzinga-all-access-show-on-friday-september-17-2021-301376275.html

SOURCE Citius Pharmaceuticals, Inc.